Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24506459 | 0.83 | HDAC8 (0.42) | KMT2APOLBHPGDALDH1A1MEN1 | |
| SCHEMBL20442107 | 0.77 | KMT2A (0.38) | KMT2APOLBHPGDALDH1A1NAMPT | |
| SCHEMBL24343792 | 0.76 | KMT2A (0.45) | KMT2APOLBHPGDALDH1A1MEN1 | |
| SCHEMBL246975 | 0.74 | POLB (0.48) | KMT2APOLBHPGDALDH1A1MEN1 | |
| SCHEMBL23107334 | 0.73 | — | — | |
| SCHEMBL22811976 | 0.72 | POLB (0.36) | KMT2APOLBHTTTHRATHRB | |
| SCHEMBL21603864 | 0.71 | — | — | |
| SCHEMBL24344113 | 0.71 | KMT2A (0.41) | KMT2APOLBHPGDALDH1A1NAMPT | |
| SCHEMBL24992694 | 0.70 | KMT2A (0.40) | KMT2APOLBHPGDALDH1A1HTT | |
| SCHEMBL22811864 | 0.69 | KMT2A (0.36) | KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11111229-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3799872-A1 | TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS | Forma Therapeutics, Inc. (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3071203-B1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369642-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-10336722-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190127347-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KMT2A 221/4885POLB 783/4885HPGD 3324/4885 |
| US-20190127347-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KMT2A 221/4885POLB 783/4885HPGD 3324/4885 |
| US-10336722-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | KMT2A 221/4885POLB 783/4885HPGD 3324/4885 |
| US-11111229-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | KMT2A 221/4885POLB 783/4885HPGD 3324/4885 |
| US-20200369642-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KMT2A 221/4885POLB 783/4885HPGD 3324/4885 |
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KMT2A 221/4885POLB 783/4885HPGD 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.